Back to top
more

Innoviva (INVA)

(Delayed Data from NSDQ)

$15.23 USD

15.23
492,419

+0.12 (0.79%)

Updated May 1, 2024 04:00 PM ET

After-Market: $15.30 +0.07 (0.46%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 23% (194 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Innoviva (INVA) Misses Q2 Earnings Estimates

by Zacks Equity Research

Innoviva (INVA) delivered earnings and revenue surprises of -90.91% and 4.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Innoviva (INVA) Q2 Earnings Expected to Decline

by Zacks Equity Research

Innoviva (INVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 0.78% and 0.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests

by Zacks Equity Research

Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva???s Trelegy royalty shares.

Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva

by Zacks Equity Research

Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.

Innoviva (INVA) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Innoviva (INVA) delivered earnings and revenue surprises of 5% and 76.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Bellus Health (BLU) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Bellus Health (BLU) and Innoviva (INVA) have performed compared to their sector so far this year.

Earnings Preview: Innoviva (INVA) Q1 Earnings Expected to Decline

by Zacks Equity Research

Innoviva (INVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Johnson & Johnson (JNJ) Tops Q1 Earnings Estimates

by Zacks Equity Research

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.69% and 1.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 Reasons to Add Novo Nordisk (NVO) Stock to Your Portfolio

by Zacks Equity Research

Novo Nordisk's (NVO) portfolio of marketed drugs are driving year over year growth. The company has one of the broadest diabetes portfolios in the industry.

Pfizer (PFE) to Boost RSV Portfolio With ReViral Acquisition

by Zacks Equity Research

Pfizer (PFE) inks an agreement to acquire ReViral for up to $525 million, which will add the latter's respiratory syncytial virus therapeutic candidates to its portfolio.

Zacks.com featured highlights include Meridian Bioscience, Innoviva, OP Bancorp and United Fire Group

by Zacks Equity Research

Meridian Bioscience, Innoviva, OP Bancorp and United Fire Group are part of Screen of the Week article.

Novartis (NVS) Gets FDA Nod for Vijoice in Rare Disorder

by Zacks Equity Research

The FDA approves Novartis' (NVS) Vijoice (alpelisib) for the treatment of select patients with PIK3CA-related overgrowth spectrum.

Nilanjan Banerjee headshot

Bet on These 4 Low-Beta Stocks to Combat Market Volatility

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), OP Bancorp (OPBK) and United Fire Group (UFCS) are well poised to gain.

Is Innoviva (INVA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Innoviva (INVA) and McKesson (MCK) have performed compared to their sector so far this year.

J&J (JNJ) Gets FDA Nod for HIV Jab, Cabenuva, in Adolescents

by Zacks Equity Research

The FDA approves Johnson & Johnson's (JNJ) Cabenuva for treating HIV-1 in virologically suppressed adolescents aged 12 years and above.

Novo Nordisk (NVO) Gets FDA Nod for Ozempic's Label Expansion

by Zacks Equity Research

The FDA approves Novo Nordisk's (NVO) Ozempic 2.0 mg dose for the treatment of adults with type II diabetes. The medicine is now approved at 0.5 mg, 1.0 mg and 2.0 mg doses for the given indication.

Lilly (LLY) Gets CRL from FDA for Sintilimab in Lung Cancer

by Zacks Equity Research

Lilly (LLY) gets a complete response letter from the FDA for the biologics license application for sintilimab plus pemetrexed and platinum chemotherapy for treating first-line lung cancer.

Novartis' (NVS) Pluvicto Gets FDA Nod for Advanced Prostate Cancer

by Zacks Equity Research

The FDA okays Novartis' (NVS) targeted radioligand therapy Pluvicto to treat PSMA-positive metastatic castration-resistant prostate cancer.

Merck (MRK) Stops Keytruda-Lynparza Combo Prostate Cancer Study

by Zacks Equity Research

Merck (MRK) decides to discontinue a late-stage prostate cancer study evaluating Keytruda in combination with AstraZeneca's Lynparza, following its failure to demonstrate a benefit in overall survival.

Sanofi's (SNY) Breast Cancer Candidate Misses Goal in Study

by Zacks Equity Research

Sanofi's (SNY) phase II AMEERA-3 study, investigating amcenestrant in ER+/HER2- advanced/metastatic breast cancer, fails to meet the primary endpoint.

Has Henry Schein (HSIC) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Henry Schein (HSIC) and Innoviva (INVA) have performed compared to their sector so far this year.

Bayer (BAYRY) to Divest a Business Unit to Cinven for $2.6B

by Zacks Equity Research

Bayer (BAYRY) to sell off its Environmental Science Professional business unit to Cinven for $2.6 billion. The company plans to focus on core agricultural businesses.

Bayer (BAYRY) Files for Nubeqa's Label Expansion in US & EU

by Zacks Equity Research

Bayer (BAYRY) submits regulatory applications to the FDA and the EMA, seeking approval for a new indication of Nubeqa for treating metastatic hormone-sensitive prostate cancer.

Zacks.com featured highlights include Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences

by Zacks Equity Research

Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences are included in this blog.